Navigation Links
MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/14/2008

rolling

interest $(3,644,376) $(9,477,927) $(17,686,783) $(23,140,917)

Loss (gain)

attributable to

noncontrolling

interest (62,875) - 180,030 -

Net loss $(3,707,251) $(9,477,927) $(17,506,753) $(23,140,917)

Basic and diluted

net loss per share $(0.07) $(0.21) $(0.32) $(0.57)

Shares used in

calculation of

basic and diluted

net loss per share 56,024,953 45,348,396 54,660,128 40,890,735

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

June 30, 2008 December 31, 2007

ASSETS

Current assets:

Cash and cash equivalents $10,254,039 $1,951,715

Marketable securities 2,372,483 -

Accounts receivable, net 703,655 687,787

Inventories, net 456,173 687,933

Prepaid expenses and other current assets 1,961,526 1,142,905

Total current assets 15,747,876 4,470,340

Property and equipment, net 9,316,781 10,928,659

Restricted cash 872,180 872,180

Deposits and other assets 111,599 174,965

Intangible assets, net 6,640,813 7,219,651

Total assets $32,689,249 $23,665,795 LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:

Accounts payable $1,468,170 $1,659,752

Accrued expenses 5,344,762
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
2. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
5. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
6. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
7. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
8. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
9. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
10. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
11. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Recently, KORT Richmond, 5006 Atwood Drive, added a ... of life. The program works with those new to prosthetic ... but are still having difficulty. , According to the ... with limb loss in the United States. The main causes ... peripheral arterial disease – trauma (45%) and cancer (less than ...
(Date:5/28/2015)... Bronx, NY (PRWEB) May 28, 2015 ... Urgent Care are proud to present Dr. Alicia Almendral ... will be a big part of the newly opened ... very finest in modern cosmetic treatments. , Dr. Almendral ... experienced in the latest anti-aging and cosmetic enhancement techniques. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
(Date:5/28/2015)... 28, 2015 Dr. Jenyons’ Medical ... exclusive deal to patients looking to undergo its advanced ... 30, patients will be able to get a single ... just $600. For a three-treatment package, which costs $1,800, ... no cost. , Dr. Juanita Jenyons, M.D., says Dr. ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... Not enough Scottish children are receiving MMR shots, say ... 92.1 per cent of two-year-olds were given the jab, which protects ... 95 per cent. , Yet, this is an ... cent. ,MMR vaccines were introduced in 1988, but ...
... medicine of Sanofi-Aventis will be made indigenously in Thailand. This ... ,As per the offer made by Sanofa-Aventis, the health ministry ... the drug. The statement released by the drug firm states ... poorer Thai patients. According to a health official the company ...
... rice bran could reduce the risk of intestinal cancer.// ... Department of Cancer Studies and Molecular Medicine, University of Leicester. ... in the laboratory has produced promising results. ... Cancer. ,The results of a controlled laboratory ...
... cancer patients unable to undergo surgery have another safe ... a new study. ,The Brown Medical ... ablation used to treat early-stage, inoperable cancer resulted in ... achieved through external beam radiation (EBT), a decades-old alternative ...
... Scientists have created the world's first human-sheep chimera - which ... ,The sheep have 15 per cent human cells ... brings the prospect of animal organs being transplanted into humans ... the University of Nevada, has spent seven years and ?5 ...
... Rift Valley Fever (RVF) among animals began on 18 ... the beginning// of February 2007 in Arusha region. A ... Country Office, WHO Regional Office for Africa, Centers for ... including active case finding and specimen collection. Two cases ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:RF Ablation a Safe Alternative Option for Treating Lung Cancer 2Health News:Now Scientists Create a Sheep That's 15% Human 2Health News:Rift Valley Fever in the United Republic of Tanzania 2
(Date:5/28/2015)... Texas , May 28, 2015   Lexicon ... that Lexicon management will present at the Jefferies 2015 ... a.m. Eastern Time in New York ... clinical development programs and milestones. A webcast ... at www.lexpharma.com . An archived version of the ...
(Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
(Date:5/28/2015)... MONICA, Calif. , May 28, 2015 ... doctors to check a state prescription database before prescribing ... addiction and thousands of overdose deaths. SB ... Bell Gardens , will require prescribers to ... (CURES) before prescribing Schedule II and III drugs, like ...
Breaking Medicine Technology:Lexicon To Present At The Jefferies 2015 Healthcare Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce large devices for vascular intervention....
Medicine Products: